BioCentury
ARTICLE | Company News

Ability Pharmaceuticals, SciClone deal

May 23, 2016 7:00 AM UTC

Ability granted SciClone exclusive rights to develop and commercialize ABTL0812 in Taiwan, Vietnam and China, including Hong Kong and Macau. Ability will receive up to $20 million, which includes an ...